Genen­tech dives deep­er in­to the mi­cro­bio­me, ink­ing $534M deal with Mi­cro­bi­ot­i­ca to de­vel­op IBD meds

Roche’s Genen­tech unit is dou­bling down on its study of the mi­cro­bio­me, ink­ing a new deal to­day worth up to $500 mil­lion to de­vel­op meds based on study­ing the gut flo­ra.

The deal is with Cam­bridge, UK-based start­up Mi­cro­bi­ot­i­ca, a spin­out of the Well­come Sanger In­sti­tute. The duo is plan­ning a mul­ti-year part­ner­ship to dis­cov­er, de­vel­op, and com­mer­cial­ize med­i­cines for in­flam­ma­to­ry bow­el dis­ease (IBD).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER